Tower Group International, Ltd. (NASDAQ: TWGP) - For an in-depth report on Tower Group International, Ltd. follow: www.BullTrends.com/stockquote/TWGP
Shares of TWGP closed up 35.88% on about 6 million shares traded. The stock was one of the biggest gainers on the NASDAQ. Tower Group and ACP Re entered into an amendment to the merger agreement originally announced earlier this year. The companies have reduced the per-share consideration for Tower common shares to $2.50 a share from $3 and reduced the termination fee that Tower be have to pay if the merger agreement was terminated.
Liquidmetal Technologies Inc. (OTCBB: LQMT) - For an in-depth report on Liquidmetal Technologies Inc. follow: www.BullTrends.com/stockquote/LQMT
Liquidmetal Technologies closed up 6.84% on about 3.1 million shares traded on Thursday. The stock was one of the biggest gainers and most active stocks in the OTCBB market. The company r reported results for the quarter ended March 31, 2014. During Q1 the company announced its first commercially available non-beryllium alloy and the hiring of a World-Wide VP of Sales and Support.
Ford Motor Co. (NYSE: F) - For an in-depth report on Ford Motor Co follow: www.BullTrends.com/stockquote/F
Shares of Ford Motor Co. closed up nearly 3% on Thursday with about 36.7 million shares traded. The stock was one of the most active stocks on the NYSE. The company announced that it will repurchase up to 116 million shares. About 103 million of these shares will be repurchased to offset the dilutive effect of potential conversions of Ford’s 4.25% senior convertible notes that are due Nov 15, 2016.
Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) - For an in-depth report on Chelsea Therapeutics International Ltd. follow: www.BullTrends.com/stockquote/CHTP
Shares of Chelsea Therapeutics closed up nearly 32% on Thursday with almost 67 million shares traded. The stock was one of the biggest advancers on the NASDAQ.. H. Lundbeck is to buy Chelsea Therapeutics for up to $658 million. The deal twould give H. Lundbeck the rights to the U.S firm's neurology drug Northera.
Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.